Prions and protein-folding diseases

Journal of Internal Medicine

Volumn 270, Issue 1, 2011, Pages 1-14

  Norrby, E ^a  

^a ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

Author keywords

Iatrogenic disease; Prions; Protein folding

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CELL PROTEIN; DNA; GROWTH HORMONE; HISTONE; METHIONINE; NUCLEIC ACID; POLYGLUTAMINE; POLYPEPTIDE; PRION PROTEIN; SYNTHETIC PEPTIDE; UNTRANSLATED RNA; VALINE; YELLOW FEVER VACCINE;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN DEGENERATION; BRAIN SURGERY; BRAIN TISSUE; CANNIBALISM; CELL DESTRUCTION; CELL PROTECTION; CENTRAL NERVOUS SYSTEM; CORNEA TRANSPLANTATION; CREUTZFELDT JAKOB DISEASE; CYTOPATHOGENIC EFFECT; DEGENERATIVE DISEASE; DISEASE TRANSMISSION; DURA MATER; EPIDEMIC; FASCIA LATA; FOOD CONTAMINATION; FOOD INTAKE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HEMOPHILIA; HEPATITIS B VIRUS; HISTOPATHOLOGY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHYSIS; IATROGENIC DISEASE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INFECTION RISK; INFLAMMATION; KURU; LIFESPAN; LONG TERM MEMORY; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; NEUROLOGIC DISEASE; NEUROSURGERY; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; OCCUPATIONAL HAZARD; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECOMBINANT DNA TECHNOLOGY; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPINAL CORD; VIRUS ENVELOPE; VIRUS REPLICATION;

ANIMALS; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; PRIONS; PROTEOSTASIS DEFICIENCIES;

EID: 79959366068     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02387.x     Document Type: Review

References (80)

1. Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea: the endemic occurrence of "kuru" in the native population. N Engl J Med 1957; 257: 974-8.
2. Hadlow WJ. Scrapie and kuru. Lancet 1959; 2: 289-90.
3. Gajdusek DC, Gibbs CJ Jr, Alpers M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 1966; 209: 794-6.
4. Gibbs CJ Jr, Gajdusek DC, Asher DM et al. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 1968; 161: 388-9.
5. Glasse RM. Cannibalism in the kuru region of New Guinea. Trans N Y Acad Sci 1967; 29: 748-54.
6. st century - an acquired human prion disease with very long incubation periods. Lancet 2006; 367: 2068-74.
7. Dorsey KA, Zou S, Schonberger LB et al. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 2009; 49: 977-84.
8. Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE. Purification and structural studies of a major scrapie prion protein. Cell 1984; 38: 127-34.
9. Prusiner SB. Prions. In: Frängsmyr T, ed. Nobel Lecture. Stockholm: Almqvist & Wiksell International, 1997; 268-323.
10. Oesch B, Westaway D, Wälchli M et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1986; 46: 417-28.
11. Büeler H, Fischer M, Lang Y et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992; 356: 577-82.
12. Büeler H, Aguzzi A, Sailer A et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 1339-47.
13. Prusiner SB, Groth D, Serban A et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 1993; 90: 10608-12.
14. Wille H, Prusiner SB, Cohen FE. Scrapie infectivity is independent of amyloid staining properties of the N-terminally truncated prion protein. J Struct Biol 2000; 130: 323-38.
15. Donne DG, Viles JH, Groth D et al. Structure of the recombinant full-length hamster protein PrP (29-231): the N terminus is highly flexible. Proc Natl Acad Sci USA 1997; 94: 7279-82.
16. Riek R, Hornemann S, Wider G, Glockshuber R, Wüthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP (23-231). FEBS Lett 1997; 413: 282-8.
17. Horwich AL, Weissman JS. Deadly conformations - Protein misfolding in prion disease. Cell 1997; 89: 499-510.
18. Houston F, McCutcheon S, Goldmnann W et al. Prion diseases are effectively transmitted by blood transfusion in sheep. Blood 2008; 112: 4739-45.
19. Brown P. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007; 13: 33-40.
20. Duffy P, Wolf J, Collins G, DeVoe AG, Steeten B, Cowen D. Possible person to person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974; 299: 692-3.
21. Will RG, Mathews WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1982; 45: 235-8.
22. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
23. The National Creutzfeldt-Jakob Disease Surveillance Unit (NCJDSU), University of Edinburgh, UK, Available at:, Accessed November 30, 2010.
24. Kaski D, Mead S, Hyare H et al. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 2009; 374: 2128.
25. Llewelyn CA, Hewitt RE, Knight RSG et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
26. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
27. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immunol 1983; 41: 154-61.
28. Gregori L, McCombie DP, Palmer D, Sowemimo-Coker AO, Giulivi A, Rohwer RG. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 264: 529-31.
29. Alper T, Cramp WA, Haig DA, Clarke MC. Does the agent of scrapie replicate without nucleic acid? Nature 1967; 214: 764-6.
30. Griffith JS. Self-replication and scrapie. Nature 1967; 215: 1043-4.
31. Poelser G, Berting A, Kindermann J et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang 2008; 94: 184-92.
32. Svae T-E, Neisser-Svae A, Bailey A et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transf Apheres Sci 2008; 39: 59-67.
33. Gregori L, Lambert B, Gurgel P et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2009; 46: 1152-61.
34. Neisser-Svae A, Bailey A, Gregori L et al. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent(S/D)-treated plasma OctaplasLG. Vox Sang 2009; 97: 226-33.
35. sc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009; 97: 219-25.
36. Health Protection Agency. Variant CJD and plasma products, 2009.
37. Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004; 116: 313-27.
38. Aguzzi A, Calella AM. Prions: Protein aggregation and infectious disease. Physiol Rev 2009; 89: 1105-52.
39. Caughey B, Baron GS. Prions and their partners in crime. Nature 2006; 443: 803-10.
40. Ramijak S, Asif AR, Armstrong VW et al. Physiological role of the cellular prion protein (PrP-C): protein profiling study in two cell culture systems. J Proteome Res 2008; 7: 2681-95.
41. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008; 88: 673-728.
42. Colby DW, Prusiner SB. Prions. In: Morimoto R, Kelly J, Selkoe D, ed. Additional Perspectives on Protein Homeostasis. Cold Spring Harb Perspect Biol doi:
43. Chesebro B, Trifilo M, Race R et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 104: 1435-9.
44. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter Jw. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 1128-33.
45. Bremer J, Baumann F, Tiberi C et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010; 13: 310-18. doi:.
46. Chien P, Weissman JS, De Pace AH. Emerging principles of conformation-based prion inheritance. Annu Rev Biochem 2004; 73: 617-56.
47. Ross ED, Minton A, Wickner RB. Prion domains: sequences, structures and interactions. Nat Cell Biol 2005; 7: 1039-44.
48. Alberti S, Halfmann R, King O, Kapila A, Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 2009; 137: 146-58.
49. Halfmann R, Alberti S, Lindquist S. Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol 2010; 20: 125-34.
50. Halfmann R, Lindquist S. Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science 2010; 330: 629-32.
51. Fraser H, Dickinson AG. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J Comp Pathol 1973; 83: 29-40.
52. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissman C. Darwinian evolution of prions in cell culture. Science 2010; 327: 869-72.
53. Chesebro B, Race B, Meade-White K et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion membrane anchoring. PLoS Pathog 2010; 6: e1000800.
54. Klingeborn M, Race B, Meade-White KD, Rosenke R, Striebel JF, Chesebro B Crucial role for prion protein membrane anchoring in the neuroinvasion and neural spread of prion infection. J Virol 2011; 85: 1484-94. PubMed PMID: 21123371.
55. Nelson R, Sawaya MR, Balbirnie M et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005; 435: 773-8.
56. Sawaya MR, Sambashivan S, Nelson R et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 2007; 447: 453-7.
57. Wiltzius JJ, Landau M, Nelson R et al. Molecular mechanisms of protein-encoded inheritance. Nat Struct Mol Biol 2009; 16: 973-8.
58. Tamgüney G, Giles K, Bouzamondo-Bernstein E et al. Genes contributing to prion pathogenesis. J Gen Virol 2008; 89: 1777-88.
59. Sigurdson CJ, Nilsson KP, Hornemann S et al. De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci 2009; 106: 304-9.
60. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411: 810-3.
61. Castilla J, Saá P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell 2005; 121: 136-44.
62. Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 2007; 104: 9741-6.
63. Barria MA, Mukherjee A, Gonzales-Romero D et al. De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog 2009; 5: e1000421.
64. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with a bacterially expressed recombinant prion protein. Science 2010; 327: 1132-5.
65. Kaneko K, Wille H, Mehlhorn I et al. Molecular properties of complexes formed between the prion protein and synthetic peptides. J Mol Biol 1997; 270: 574-86.
66. Legname G, Baskakkov IV, Nguyen H-OB et al. Synthetic mammalian prions. Science 2004; 305: 673-6.
67. Legname G, Nguyen H-OB, Peretz D et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specific phenotypes. Proc Natl Acad Sci 2006; 103: 19105-10.
68. Colby DW, Giles K, Legname G et al. Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci 2009; 106: 20417-22.
69. Colby DW, Wain R, Baskakov IV et al. Protease-sensitive synthetic prions. PLoS Pathog 2010; 6: e1000736.
70. Edgeworth JA, Gros N, Alden J et al. Spontaneous generation of mammalian prions. Proc Natl Acad Sci 2010; 107: 14402-6. DOI:.
71. Aguzzi A, Baumann F, Bremer J. The prion's elusive reason for being. Annu Rev Neurosci 2008; 31: 439-77.
72. Aguzzi A. Beyond the prion principle. Nature 2009; 459: 924-5.
73. Meyer-Luehmann M, Coomaraswamy J, Bolmont T et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781-4.
74. Eisele YS, Bolmont T, Heikenwalder M et al. Indiction of cerebral beta-amyloidosis: intracerebral versus systemic A-beta inoculation. Proc Natl Acad Sci 2009; 106: 12926-31.
75. Clavaguera F, Bolmont T, Crowther RA et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-13.
76. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11: 209-25.
77. Lundmark K, Westermark GT, Olsen A, Westermark P. Protein fibrils in nature can enhance amyloid protein a amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci USA 2005; 102: 6098-102.
78. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci 2009; 106: 12571-2.
79. Höppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343: 411-9.
80. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. Aplysia CFEB can form prion-like multimers in sensory neurons that contribute to long-tem facilitation. Cell 2010; 140: 421-35.